Oral squamous cell carcinoma occurring secondary to oral lichen planus around the dental implant: A case report
Oral Science International · 2019
DOI: 10.1002/osi2.1008 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oral Science International, 2019. Verfasst von Kazuma Noguchi und 5 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Oral lichen planus ( OLP ) or chronic inflammation is a risk factor for oral squamous cell carcinoma ( OSCC ). We report a case of OSCC derived from OLP around dental implant ( DI ) in a 78‐year‐old woman. First incisional biopsy of this region was diagnosed as OLP . Epidermal hyperplasia was revealed in a second biopsy performed after 1 year and 4 months. After 8 months, OSCC occurred on the same site and surgical treatment was successfully performed. This case may present a process of malignant conversion from OLP to OSCC via epithelial hyperplasia. There is a possibility that periimplantitis was involved in this change.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Noguchi, K., Moridera, K., Sotsuka, Y., Yamanegi, K., Takaoka, K., & Kishimoto, H. (2019). Oral squamous cell carcinoma occurring secondary to oral lichen planus around the dental implant: A case report. Oral Science International. https://doi.org/10.1002/osi2.1008
Vancouver
Noguchi K, Moridera K, Sotsuka Y, Yamanegi K, Takaoka K, Kishimoto H. Oral squamous cell carcinoma occurring secondary to oral lichen planus around the dental implant: A case report. Oral Science International. 2019. doi:10.1002/osi2.1008
BibTeX
@article{Noguchi2019,
author = {Noguchi, Kazuma and Moridera, Kuniyasu and Sotsuka, Yohei and Yamanegi, Koji and Takaoka, Kazuki and Kishimoto, Hiromitsu},
title = {Oral squamous cell carcinoma occurring secondary to oral lichen planus around the dental implant: A case report},
journal = {Oral Science International},
year = {2019},
doi = {10.1002/osi2.1008}
}
EUVIMED